Schwartz et al. [144] reported that iron chelators may be particularly effective in tumours with high hepcidin and low ferroportin levels, as these tumours sequester iron intracellularly, rendering them more susceptible to iron depletion. This evidence concerns the gene HAMP and neoplasm.